Histopathology providers merge to serve biopharma, CRO industry as single company backed by PE

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/anyaivanova)
(Image: Getty/anyaivanova)

Related tags: Histopathology, Pathology, Private equity, Preclinical contract research

Histo-Scientific Research Laboratories and Vet Path Services have merged to create one company dedicated to providing histology, pathology, and archiving services to the biopharmaceutical, medical device, and contract research industries.

The companies will become one to meet an increasing demand for histopathology services in the research and preclinical therapeutics markets.

“The owners of the two companies saw an opportunity to expand value to clients, especially for histology and pathology services, as a single combined entity,”​ HSRL CEO Tom Galati told us.

Histo-Scientific Research Laboratories (HSRL) service offering includes tissue analyses, efficacy determination for new compounds and devices, toxicologic evaluation, and pathology reporting for good laboratory practices (GLP) studies. 

Vet Path Services’ (VPS) GLP-compliant archival offering includes cold (5°C and -20°C) and ultra-low-temperature (-80°C) material storage, among other histology and pathology services.

The combined company has offices in Mt. Jackson, VA, Mason, OH, and Worcester, MA – and has plans to “significantly”​ expand its Worcester site.

Following the merger, the middle market private equity (PE) firm Ampersand Capital Partners also has invested in the company.

“Ampersand seeks out, and invests in the top players in their respective industry segments. We target companies that have a differentiated approach and operate in high growth markets,”​ said David Anderson, PhD, partner, Ampersand Capital Partners.

Anderson told us, “Both HSRL and VPS meet these criteria and together create a formidable company to service the pre-clinical histopathology market.”

Amersand’s investment follows several​ in the industry. Most recently, the PE firm in November acquired Pacific Biomarkers​ with plans to merge the CRO with Neomed-Labs, which it bought in September​.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Related suppliers

Follow us

Products

View more

Webinars